A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Single- and Multiple-Ascending-Dose Study to Determine Initial Safety, Tolerability, and Pharmacokinetics of GDC-0134 in Patients With Amyotrophic Lateral Sclerosis
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2017
At a glance
- Drugs GDC 0134 (Primary) ; Caffeine; Midazolam; Rabeprazole
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; First in man
- Sponsors Genentech
- 02 Oct 2017 Planned number of patients changed from 48 to 72.
- 02 Oct 2017 Planned End Date changed from 30 Sep 2017 to 30 Sep 2018.
- 02 Oct 2017 Planned primary completion date changed from 30 Sep 2017 to 31 Aug 2018.